TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22981045

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) plus conventional sepsis treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (Conventional sepsis treatment only)
Number of subjects: 12
Study: 21306237

Group type: EXPERIMENTAL
Intervention: Sunitinib at a dose of 37.5 mg per day
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 18164937

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 573
Study: 16881243

Group type: EXPERIMENTAL
Intervention: Observation tool for evaluating parent-child interaction; details on dosage and duration not applicable.
Number of subjects: 0
Study: 12953740

Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Protocol deviations
Number of subjects: 28
Study: 11202321

Group type: EXPERIMENTAL
Intervention: Closed treatment
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Open treatment
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 8985844

Group type: EXPERIMENTAL
Intervention: Formula beta (24% palmitic acid, 66% esterified to beta-position)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formula intermediate (24% palmitic acid, 39% esterified to beta-position)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regular formula (20% palmitic acid, 13% esterified to beta-position)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formula beta
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formula intermediate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regular formula
Number of subjects: 27
Study: 8517512

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 25 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine 5 mg in normal saline 25 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combination of bupivacaine 0.5% 12.5 ml and 5 mg of morphine in normal saline 25 ml
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normal saline 25 ml
Number of subjects: 40
Study: 3031840

Group type: EXPERIMENTAL
Intervention: Misonidazole 1.2 g/m2 orally on treatment day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 41
Study: 29151116

Group type: EXPERIMENTAL
Intervention: Silodosin for 3 days (Group 3)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Silodosin for 1 day (Group 2)
Number of subjects: 147

Group type: COMPARATOR
Intervention: No alpha-1 blocker (Group 1)
Number of subjects: 147
Study: 24886179

Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy (iCBT) program consisting of 8 weekly modules with post-session feedback support.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group receiving access to the treatment at week 8.
Number of subjects: 0
Study: 22699254

Group type: EXPERIMENTAL
Intervention: Auditory training (18 sessions of 20 minutes each with feedback)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 18
Study: 20423913

Group type: EXPERIMENTAL
Intervention: SGN-30 with GVD (gemcitabine, vinorelbine, and pegylated liposomal doxorubicin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo with GVD (gemcitabine, vinorelbine, and pegylated liposomal doxorubicin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SGN-30 with GVD
Number of subjects: 30
Study: 18602724

Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal protein D (PD)-conjugate study vaccine
Number of subjects: 4968

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (HAV) (control)
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal PD-conjugate study vaccine
Number of subjects: 4968

Group type: EXPERIMENTAL
Intervention: Hexavalent DTPa-HBV-IPV/Hib vaccine
Number of subjects: 4968
Study: 16037183

Group type: EXPERIMENTAL
Intervention: 20 degrees head-up position
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 20 degrees head-down position
Number of subjects: 3
Study: 12271279

Group type: EXPERIMENTAL
Intervention: Postoperative imiquimod 5% cream applied for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postoperative imiquimod 5% cream
Number of subjects: 12
Study: 10332676

Group type: EXPERIMENTAL
Intervention: Multiple reminders (additional reminders at 3, 6, and 9 months)
Number of subjects: 19523

Group type: COMPARATOR
Intervention: Single reminder (no additional reminders)
Number of subjects: 19523

Group type: EXPERIMENTAL
Intervention: Multiple reminders
Number of subjects: 19523

Group type: COMPARATOR
Intervention: Single reminder
Number of subjects: 19523
Study: 7472703

Group type: EXPERIMENTAL
Intervention: Cardiology fellows
Number of subjects: 6

Group type: COMPARATOR
Intervention: Physician performance
Number of subjects: 6
Study: 1973470

Group type: EXPERIMENTAL
Intervention: Low-fat vegetarian diet, stopping smoking, stress management training, and moderate exercise
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 28
Study: 415643

Group type: EXPERIMENTAL
Intervention: Gold salt treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 30856689

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg daily for 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 52
Study: 28544504

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Befriending
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both CBT and Befriending
Number of subjects: 110
Study: 26296950

Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Number of subjects: 225

Group type: COMPARATOR
Intervention: Low-flow oxygen therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: High-flow oxygen therapy
Number of subjects: 225
Study: 23668727

Group type: EXPERIMENTAL
Intervention: Validation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reflection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 21707627

Group type: EXPERIMENTAL
Intervention: Paranoid schizophrenia
Number of subjects: 374

Group type: COMPARATOR
Intervention: Nonparanoid schizophrenia
Number of subjects: 374
Study: 20023333

Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient care (MOC) programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to patient compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitators to patient compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General perception of the MOC programme
Number of subjects: 0
Study: 16257026

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 15564167

Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam 4 g/500 mg every 8 hours
Number of subjects: 293

Group type: COMPARATOR
Intervention: imipenem/cilastatin 500 mg/500 mg every 6 hours
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 293

Group type: COMPARATOR
Intervention: imipenem/cilastatin
Number of subjects: 293
Study: 11745931

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 MU three times weekly for 52 weeks)
Number of subjects: 147
Study: 9267858

Group type: EXPERIMENTAL
Intervention: Ceruletide (CCK analog)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7970859

Group type: EXPERIMENTAL
Intervention: Walking without parallel bars
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Providing 40% body weight support (BWS) while walking without parallel bars
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher treadmill speeds
Number of subjects: 0
Study: 3499066

Group type: EXPERIMENTAL
Intervention: Pyridoxine HCl 50 mg/d
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29110963

Group type: EXPERIMENTAL
Intervention: Water with simethicone (B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Water, simethicone and pronase (C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Water alone (A)
Number of subjects: 120
Study: 27600061

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 75
Study: 25546985

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 24
Study: 22631063

Group type: EXPERIMENTAL
Intervention: 24‐hour steroid avoidance group (n=41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard protocol group (n=41)
Number of subjects: 82
Study: 21190597

Group type: EXPERIMENTAL
Intervention: Dahuang Fuzi decoction enema
Number of subjects: 206

Group type: COMPARATOR
Intervention: Soapsuds enema (control group)
Number of subjects: 206
Study: 18291612

Group type: EXPERIMENTAL
Intervention: One-operator technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Two-operator technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 32
Study: 16985020

Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 546

Group type: COMPARATOR
Intervention: No folate supplementation
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: TSER, TSER 3R G>C, and TS 1494del6 variants
Number of subjects: 546
Study: 12838195

Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation (0.3 g/kg/day)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 649
Study: 10668338

Group type: EXPERIMENTAL
Intervention: Revascularization strategy (PTCA or CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ischemia-guided strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Revascularization strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angina-guided strategy
Number of subjects: 0
Study: 8842662

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pipecuronium
Number of subjects: 0
Study: 1504160

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 14
Study: 6857882

Group type: EXPERIMENTAL
Intervention: Intermittent leg compression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elastic stockings
Number of subjects: 0
Study: 29956215

Group type: EXPERIMENTAL
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC) 100 mg, 150 mg, and 200 mg administered orally
Number of subjects: 60

Group type: COMPARATOR
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC)
Number of subjects: 60
Study: 29693605

Group type: EXPERIMENTAL
Intervention: wCDSMP
Number of subjects: 181
Study: 27208375

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 25209520

Group type: EXPERIMENTAL
Intervention: Ozenoxacin 2% cream applied once daily (0.2 g per application)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ozenoxacin 2% cream applied twice daily (0.2 g per application, 12 h apart)
Number of subjects: 24
Study: 22497803

Group type: EXPERIMENTAL
Intervention: Low-intensity water exercise program (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Muscular resistance water exercise intervention (group 2)
Number of subjects: 21
Study: 19129749

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17496672

Group type: EXPERIMENTAL
Intervention: Active Communication Education (ACE) program
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo social program followed by ACE program
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: ACE program only
Number of subjects: 178
Study: 15353870

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 154

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 11601838

Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 9586849

Group type: EXPERIMENTAL
Intervention: 15 mg Zolpidem (Zol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg Diazepam (Dz)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg Oxazepam (Ox)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5 mg Zopiclone (Zop)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol (EOH; 0.65 + 0.35 g x kg(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7989704

Group type: EXPERIMENTAL
Intervention: Ribavirin (800, 1000, or 1200 mg/kg per day)
Number of subjects: 18
Study: 2499922

Group type: EXPERIMENTAL
Intervention: Rioprostil 100 micrograms twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 60
Study: 29910013

Group type: EXPERIMENTAL
Intervention: Mindfulness based relapse prevention (MBRP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 79
Study: 28270105

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (MET-CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both MET-CBT and brief advice
Number of subjects: 0
Study: 26353424

Group type: EXPERIMENTAL
Intervention: 1 500 ml of Ringers lactate
Number of subjects: 3

Group type: COMPARATOR
Intervention: 500 ml of 6% pentastarch
Number of subjects: 3

Group type: COMPARATOR
Intervention: Combination of 250 ml of 6% pentastarch and 750 ml of Ringers lactate
Number of subjects: 3
Study: 23291800

Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine daily for 8 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: 4 mg risperidone daily for 8 weeks
Number of subjects: 29
Study: 20349169

Group type: EXPERIMENTAL
Intervention: Intraoperative pedography (IP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intraoperative pedography (Control)
Number of subjects: 100
Study: 18782319

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 267

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 267
Study: 16778663

Group type: EXPERIMENTAL
Intervention: Cervical myelopathy patients
Number of subjects: 129

Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 129
Study: 14571612

Group type: EXPERIMENTAL
Intervention: RT + TCM (Jingming recipe)
Number of subjects: 35

Group type: COMPARATOR
Intervention: RT
Number of subjects: 35
Study: 10813483

Group type: EXPERIMENTAL
Intervention: Quinine (7-day course)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Sickle cell trait
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Bed nets usage
Number of subjects: 173
Study: 8986916

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1454506

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 3904382

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (SK) therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 31054568

Group type: EXPERIMENTAL
Intervention: LIDO (lidocaine 1.5 mg/kg loading, 1.5 mg/kg/h infusion)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DEX (dexmedetomidine 0.5 μg/kg loading, 0.4 μg/kg/h infusion)
Number of subjects: 180

Group type: COMPARATOR
Intervention: CON (saline)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LIDO
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 180

Group type: COMPARATOR
Intervention: CON
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LIDO and DEX
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LIDO and CON
Number of subjects: 180
Study: 30107054

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (e.g., fluoroquinolones)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 26778006

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation therapy (ADT) (≥ 2 years)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Short-term androgen deprivation therapy (ADT) (< 2 years)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Short-term ADT
Number of subjects: 302
Study: 24240712

Group type: EXPERIMENTAL
Intervention: Prehospital cooling (infusion of up to 2 L of 4°C normal saline)
Number of subjects: 1359
Study: 22467889

Group type: EXPERIMENTAL
Intervention: 5% dextrose
Number of subjects: 550

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 550
Study: 20103448

Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 44

Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 44
Study: 18684310

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX)‐A injections into the upper limb
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no upper limb BTX‐A)
Number of subjects: 22
Study: 16123721

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 80
Study: 12100762

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Norepinephrine-dobutamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 16
Study: 10225503

Group type: EXPERIMENTAL
Intervention: Imagery plus eye movements
Number of subjects: 71

Group type: COMPARATOR
Intervention: Imagery alone
Number of subjects: 71
Study: 8561662

Group type: EXPERIMENTAL
Intervention: Constant stimulus condition (same erotic slide on repeated trials)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Varied stimuli condition (various erotic slides)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Repeated erotic stimulation followed by novel erotic stimulus
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Facial EMG (physiological marker of emotional experience)
Number of subjects: 74
Study: 1964751

Group type: EXPERIMENTAL
Intervention: Fragmin (low molecular weight heparin) subcutaneously (120 anti-FXa U/kg) twice daily
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard heparin (SH) as continuous intravenous infusion (480 IU kg‐1 day‐1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard heparin (SH)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Fragmin and Standard heparin (SH)
Number of subjects: 119
Study: 492872

Group type: EXPERIMENTAL
Intervention: low conflict (speed emphasized)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: low conflict (accuracy emphasized)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: intermediate conflict
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: high conflict
Number of subjects: 60
Study: 30548279

Group type: EXPERIMENTAL
Intervention: Peer Education Program Pertaining to Sexual Myths
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1178
Study: 29040012

Group type: EXPERIMENTAL
Intervention: ALLIC 2002 protocol treatment for patients with Down syndrome
Number of subjects: 41

Group type: COMPARATOR
Intervention: ALLIC 2002 protocol treatment for patients without Down syndrome
Number of subjects: 41
Study: 25133492

Group type: EXPERIMENTAL
Intervention: Six-month moderate intensity walking intervention (three times a week, 40 minutes per session, supervised and home-based)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 121
Study: 23828112

Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative blood flow
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative blood volume
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative capillary permeability
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CT perfusion measuring relative MTT
Number of subjects: 7
Study: 21138617

Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 25
Study: 18503774

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day for the first month and 8 mg/day thereafter; n = 32)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 63
Study: 17591662

Group type: EXPERIMENTAL
Intervention: Peer education supplemented with individual clinic‐based counselling
Number of subjects: 901

Group type: COMPARATOR
Intervention: Peer education only
Number of subjects: 901
Study: 12841927

Group type: EXPERIMENTAL
Intervention: Etodolac SR (400 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Diclofenac (100 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Etodolac SR
Number of subjects: 64

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 64
Study: 10885603

Group type: EXPERIMENTAL
Intervention: Combination treatment (methotrexate 100 mg/m2 and cisplatin 50 mg/m2 for 3 cycles at 2-week intervals)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Radiotherapy only (XRT)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 204
Study: 9368438

Group type: EXPERIMENTAL
Intervention: Secure (John O. Butler Co.) denture adhesive paste
Number of subjects: 25

Group type: COMPARATOR
Intervention: Other four denture adhesive pastes
Number of subjects: 25
Study: 1408479

Group type: EXPERIMENTAL
Intervention: High titer Edmonston-Zagreb vaccine at 5 to 6 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard titer Schwarz vaccine at 8 to 9 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: High titer Biken-CAM vaccine at 8 to 9 months of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 0